Russia’s sovereign wealth fund known as the Russian Direct Investment Fund (RDIF), instrumental in forming a partnership with a Russian drug development company to develop the first approved use of an antiviral for COVID-19 treatment (Avifavir), has teamed with a $10 billion conglomerate called Sistema PJSFC and a government research laboratory called Gamaleya National Research Institute of Epidemiology and Microbiology to develop a major COVID-19 vaccine production facility. Not well reported in the Western press, RDIF has supported the development of a Russian COVID-19 vaccine that is scheduled to commence clinical trials by mid-June 2020 and enter production by the fall. With vaccine trial voluntary and participant enrollment underway, this Russian vaccine is the result of a partnership between Gamaleya and another Russian defense-focused research lab.
TrialSite News offers brief breakdown of this situation; the vaccine, players and timelines as reported by the RDIF supported by ongoing background research and discussions.
Who is the RDIF?
The Russian Direct Investment Fund, which has operated in an impressive manner since the advent of COVID-19. That Russia has a...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).